Return to content in this issue

 

Predictive Factors and Optimization of Omalizumab in Chronic Spontaneous Urticaria: A Multicenter Study of 257 Patients

Ceravalls J1, Giménez-Arnau AM2, Expósito-Serrano V3, Fernández Chico N3, Lara Moya A3, Bielsa I4, Ribó P5, Mascaró-Hereza B5, Bonfill-Ortí M6, Spertino J7, Serra E7, Baliu-Piqué C8, Melé-Ninot G1

1Department of Dermatology, Hospital Universitari Sagrat Cor, Grupo QuirónSalud, Barcelona, Spain
2Department of Dermatology, Hospital de Mar Research Institute, Universitat Pompeu Fabra, Barcelona, Spain
3Department of Dermatology, Consorci Sanitari Parc Taulí, Sabadell, Spain
4Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain
5Department of Allergology, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain
6Department of Dermatology, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Spain
7 Department of Dermatology, Hospital de la Santa Creu i Sant Pau Hospital, Barcelona, Spain
8Department of Dermatology, Hospital d’Igualada-Consorci Sanitari de l’Anoia, Barcelona

J Investig Allergol Clin Immunol 2025; Vol. 35(3)
doi: 10.18176/jiaci.1053

Key words: Omalizumab, Chronic spontaneous urticaria, Optimization, Biomarkers, Algorithm